Ashanka Beligaswatte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ashanka Beligaswatte has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Boon Ming Lim
Department of Clinical Haematology and Olivia Newton John Cancer Research Institute Austin Health Melbourne Victoria Australia
2 shared publications - David Morrall Ross
Royal Adelaide Hospital, Adelaide, Australia
2 shared publications Ian Lewis
Clinical Haematology Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
2 shared publications- Jeff Szer
Clinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
2 shared publications - Luen Bik To
Directorate of Haematology, SA Pathology and Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia
2 shared publications Peter Bardy
Haematology Department, Royal Adelaide Hospital
2 shared publications
Latest Publications
- Open Access
- 20 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 689.e1-689.e13
Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study
- 20 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 689.e1-689.e13
Open AccessLong-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study
- 22 April 2019
- Published by Wiley in Clinical Endocrinology
- Vol. 91 (1) , 230-232
Rituximab for treatment of refractory insulin autoimmune syndrome associated with non‐Hodgkin B‐cell lymphoma
- 22 April 2019
- Published by Wiley in Clinical Endocrinology
- Vol. 91 (1) , 230-232
Rituximab for treatment of refractory insulin autoimmune syndrome associated with non‐Hodgkin B‐cell lymphoma
- Open Access
- 19 June 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 48 (3) , 276-285
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
Background/Aims: We sought to determine factors associated with the overall survival from relapse (OSR) of acute myeloid leukaemia (AML) after allogeneic haemopoietic stem cell transplantation (alloHSCT) and the effect of first salvage therapy and subsequent graft‐versus‐host disease (GVHD) on OSR.Methods: Data on 386 patients from nine Australian centres with relapsed AML post‐alloHSCT were collected retrospectively. OSR was calculated using the Kaplan–Meier method. Univariate and multivariate analyses were conducted using the log‐rank test and proportional hazards modelling, respectively and a prognostic index for OSR was derived from multivariate modelling.Results: On multivariate analysis, relapse within 6 months (hazard ratio (HR) 2.4, P < 0.001) and grade 3–4 acute GVHD preceding relapse (HR 2.0, P = 0.004), were associated with inferior OSR. Patients with 1–2 factors had inferior OSR compared to those with zero factors (all patients: HR 2.3, P < 0.001, patients given salvage: HR 1.8, P < 0.001). The first salvage therapy used post‐relapse was donor cell therapy (DCT) (second alloHSCT or donor lymphocyte infusion) in 75, re‐induction chemotherapy (CT) in 103, radiotherapy in 8 and interferon‐α in 6. Although re‐induction CT death rate was low (2%), survival after CT was inferior to DCT (HR 1.9, P < 0.001). No survival benefit was seen for patients who developed GVHD following salvage therapy (P = 0.405).Conclusion: Patients with AML who relapse beyond 6 months from alloHSCT without prior grade 3–4 acute GVHD have a better outcome from salvage therapy. Salvage treatments employing DCT as the initial treatment of AML relapse confer a survival advantage over CT.
- 19 June 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 48 (3) , 276-285
Open AccessAcute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
Background/Aims: We sought to determine factors associated with the overall survival from relapse (OSR) of acute myeloid leukaemia (AML) after allogeneic haemopoietic stem cell transplantation (alloHSCT) and the effect of first salvage therapy and subsequent graft‐versus‐host disease (GVHD) on OSR.Methods: Data on 386 patients from nine Australian centres with relapsed AML post‐alloHSCT were collected retrospectively. OSR was calculated using the Kaplan–Meier method. Univariate and multivariate analyses were conducted using the log‐rank test and proportional hazards modelling, respectively and a prognostic index for OSR was derived from multivariate modelling.Results: On multivariate analysis, relapse within 6 months (hazard ratio (HR) 2.4, P < 0.001) and grade 3–4 acute GVHD preceding relapse (HR 2.0, P = 0.004), were associated with inferior OSR. Patients with 1–2 factors had inferior OSR compared to those with zero factors (all patients: HR 2.3, P < 0.001, patients given salvage: HR 1.8, P < 0.001). The first salvage therapy used post‐relapse was donor cell therapy (DCT) (second alloHSCT or donor lymphocyte infusion) in 75, re‐induction chemotherapy (CT) in 103, radiotherapy in 8 and interferon‐α in 6. Although re‐induction CT death rate was low (2%), survival after CT was inferior to DCT (HR 1.9, P < 0.001). No survival benefit was seen for patients who developed GVHD following salvage therapy (P = 0.405).Conclusion: Patients with AML who relapse beyond 6 months from alloHSCT without prior grade 3–4 acute GVHD have a better outcome from salvage therapy. Salvage treatments employing DCT as the initial treatment of AML relapse confer a survival advantage over CT.
- 30 November 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (7) , 1767-1769
Sensitive monitoring of acute promyelocytic leukemia byPML-RARADNA Q-PCR
(2017). Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR. Leukemia & Lymphoma: Vol. 58, No. 7, pp. 1767-1769.
- 30 November 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (7) , 1767-1769
Sensitive monitoring of acute promyelocytic leukemia byPML-RARADNA Q-PCR
(2017). Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR. Leukemia & Lymphoma: Vol. 58, No. 7, pp. 1767-1769.
- Open Access
- 9 March 2015
- Published by Springer Nature in Leukemia
- Vol. 29 (10) , 2101-2104
A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
- 9 March 2015
- Published by Springer Nature in Leukemia
- Vol. 29 (10) , 2101-2104
Open AccessA tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
- Open Access
- 2 February 2015
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (4) , 566-572
Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis
Thymoglobulin (TG) given with conditioning for allogeneic haematopoietic SCT (alloHSCT) is effective in reducing the risk of acute and chronic GVHD (cGVHD). Whether conventional risk factors for GVHD apply to TG-conditioned alloHSCT is unknown. We retrospectively studied 356 adults from three centres who received TG 4.5 mg/kg prior to alloHSCT for haematologic malignancy. Donors were unrelated in 64%. At 3 years, OS was 61% (95% confidence interval (CI) 55–67%), cumulative incidence of relapse was 28% (95% CI 23–33%) and non-relapse mortality was 19% (14–24%). The cumulative incidences of grade 2–4, and grade 3–4 acute GVHD were 23% (95% CI 19–28%) and 10% (95% CI 6–13%), respectively. The cumulative incidence of cGVHD requiring systemic immunosuppression (cGVHD-IS) at 3 years was 32% (95% CI 27–37%). On multivariate analysis, counterintuitively, recipient age over 40 was associated with a significantly decreased risk of cGVHD-IS (P=0.001). We report for the first time a paradoxical association of older age with reduced cGVHD in TG recipients, and conclude that traditional risk factors for GVHD may behave differently in the context of pre-transplant TG.
- 2 February 2015
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (4) , 566-572
Open AccessOlder recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis
Thymoglobulin (TG) given with conditioning for allogeneic haematopoietic SCT (alloHSCT) is effective in reducing the risk of acute and chronic GVHD (cGVHD). Whether conventional risk factors for GVHD apply to TG-conditioned alloHSCT is unknown. We retrospectively studied 356 adults from three centres who received TG 4.5 mg/kg prior to alloHSCT for haematologic malignancy. Donors were unrelated in 64%. At 3 years, OS was 61% (95% confidence interval (CI) 55–67%), cumulative incidence of relapse was 28% (95% CI 23–33%) and non-relapse mortality was 19% (14–24%). The cumulative incidences of grade 2–4, and grade 3–4 acute GVHD were 23% (95% CI 19–28%) and 10% (95% CI 6–13%), respectively. The cumulative incidence of cGVHD requiring systemic immunosuppression (cGVHD-IS) at 3 years was 32% (95% CI 27–37%). On multivariate analysis, counterintuitively, recipient age over 40 was associated with a significantly decreased risk of cGVHD-IS (P=0.001). We report for the first time a paradoxical association of older age with reduced cGVHD in TG recipients, and conclude that traditional risk factors for GVHD may behave differently in the context of pre-transplant TG.
- 8 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (3) , 409-412
The mean fluorescence intensities of anti‐HLA antibodies detected using micro‐bead flow cytometry predict the risk of platelet transfusion refractoriness
Summary: There are no accepted methods to predict the development of platelet transfusion refractoriness (PTR) due to human leucocyte antigen (HLA)‐alloimmunization. Hence, matched platelets are usually given only to patients demonstrating PTR, necessarily resulting in some ineffective random donor platelets (RDPLT) transfusions. To assess its utility in predicting PTR, we retrospectively tested samples from 387 patients receiving chemotherapy for acute leukaemia or autologous transplantation using a micro‐bead flow cytometry assay. The average of the mean fluorescence intensities (avgMFI) of the class I beads in the screening assay was correlated with outcomes of RDPLT transfusions during a 2 week period. Antibodies were detected in 57 patients; 66 developed PTR, of whom 28 were alloimmunized. avgMFI usefully predicted the development of PTR (area under the receiver operating curve 0·87, 95% confidence interval: 0·77–0·96). A logistic regression model estimated the probability of PTR to be >90% when avgMFI >5440. These results indicate that micro‐bead flow cytometry assays could inform a risk‐adapted strategy for managing thrombocytopaenic HLA allo‐immunized patients.
- 8 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (3) , 409-412
The mean fluorescence intensities of anti‐HLA antibodies detected using micro‐bead flow cytometry predict the risk of platelet transfusion refractoriness
Summary: There are no accepted methods to predict the development of platelet transfusion refractoriness (PTR) due to human leucocyte antigen (HLA)‐alloimmunization. Hence, matched platelets are usually given only to patients demonstrating PTR, necessarily resulting in some ineffective random donor platelets (RDPLT) transfusions. To assess its utility in predicting PTR, we retrospectively tested samples from 387 patients receiving chemotherapy for acute leukaemia or autologous transplantation using a micro‐bead flow cytometry assay. The average of the mean fluorescence intensities (avgMFI) of the class I beads in the screening assay was correlated with outcomes of RDPLT transfusions during a 2 week period. Antibodies were detected in 57 patients; 66 developed PTR, of whom 28 were alloimmunized. avgMFI usefully predicted the development of PTR (area under the receiver operating curve 0·87, 95% confidence interval: 0·77–0·96). A logistic regression model estimated the probability of PTR to be >90% when avgMFI >5440. These results indicate that micro‐bead flow cytometry assays could inform a risk‐adapted strategy for managing thrombocytopaenic HLA allo‐immunized patients.
- 15 November 2011
- Published by Springer Nature
- p. 249-275
rHuG-CSF in Peripheral Blood Progenitor Cell Transplantation
- 15 November 2011
- Published by Springer Nature
- p. 249-275
rHuG-CSF in Peripheral Blood Progenitor Cell Transplantation
- Open Access
- 1 January 2008
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 46 (8) , 768-770
An outbreak of fatal pneumonitis caused by contamination of illicit alcohol with paraquat.
Introduction. We describe a series of unsuspected paraquat poisonings presenting as an outbreak of fatal acute pneumonitis. Exposure to paraquat occurred during the widespread practice of adding substances to alter the taste or potency of illicit alcohol. The diagnosis was suspected only after autopsy findings suggestive of paraquat toxicity were seen in the first fatality. Case series. An estimated 50 persons were exposed. Of these, 5 presented with ever and progressive dyspnoea, and died 9–30 days after exposure. We were able to trace 35 potentially exposed persons who survived, and compared them to the fatalities. Fever, headache, cough, dyspnoea, abdominal pain, hepatomegaly, and lung signs were more common among those who died. Autopsy revealed widespread renal and hepatic necrosis in the early deaths, and prominent pulmonary fibrosis in those dying later. Conclusion. This case series defines an unusual syndrome of paraquat poisoning, which should be considered in the diagnosis of outbreaks of acute pneumonitis in illicit alcohol users.
- 1 January 2008
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 46 (8) , 768-770
Open AccessAn outbreak of fatal pneumonitis caused by contamination of illicit alcohol with paraquat.
Introduction. We describe a series of unsuspected paraquat poisonings presenting as an outbreak of fatal acute pneumonitis. Exposure to paraquat occurred during the widespread practice of adding substances to alter the taste or potency of illicit alcohol. The diagnosis was suspected only after autopsy findings suggestive of paraquat toxicity were seen in the first fatality. Case series. An estimated 50 persons were exposed. Of these, 5 presented with ever and progressive dyspnoea, and died 9–30 days after exposure. We were able to trace 35 potentially exposed persons who survived, and compared them to the fatalities. Fever, headache, cough, dyspnoea, abdominal pain, hepatomegaly, and lung signs were more common among those who died. Autopsy revealed widespread renal and hepatic necrosis in the early deaths, and prominent pulmonary fibrosis in those dying later. Conclusion. This case series defines an unusual syndrome of paraquat poisoning, which should be considered in the diagnosis of outbreaks of acute pneumonitis in illicit alcohol users.